Matthew Wagoner
Overview
Explore the profile of Matthew Wagoner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McDonald J, Wagoner M, Shaikh F, Sercy E, Stewart L, Knapp E, et al.
Mil Med
. 2024 Feb;
189(11-12):2550-2561.
PMID: 38421743
Introduction: The long-term impact of deployment-related trauma on mental and physical health-related quality of life (HRQoL) among military personnel is not well understood. We describe the mental and physical HRQoL...
2.
Okai Y, Matsune K, Yamanaka K, Matsui T, Kaushik E, Harada K, et al.
J Pharmacol Toxicol Methods
. 2020 Jul;
105:106893.
PMID: 32619502
Introduction: Drug-induced inotropic change is a risk factor in drug development; thus, de-risking is desired in the early stages of drug development. Unlike proarrhythmic risk assessment using human induced pluripotent...
3.
Kohara H, Bajaj P, Yamanaka K, Miyawaki A, Harada K, Miyamoto K, et al.
Toxicol Sci
. 2019 Nov;
173(2):347-361.
PMID: 31722436
Cholestasis resulting from hepatic bile acid efflux transporter inhibition may contribute to drug-induced liver injury (DILI). This condition is a common safety-related reason for drug attrition and withdrawal. To screen...
4.
Matsui T, Miyamoto K, Yamanaka K, Okai Y, Kaushik E, Harada K, et al.
Toxicol Appl Pharmacol
. 2019 Sep;
383:114761.
PMID: 31533062
Recent developments of novel targeted therapies are contributing to the increased long-term survival of cancer patients; however, drug-induced cardiotoxicity induced by cancer drugs remains a serious problem in clinical settings....
5.
Korver W, Carsillo M, Yuan J, Idamakanti N, Wagoner M, Shi P, et al.
J Pharmacol Exp Ther
. 2019 May;
370(2):182-196.
PMID: 31085699
Ectoenzyme CD38 is increased on lymphocytes in response to an antigenic challenge and it is hypothesized that targeting these activated lymphocytes could ameliorate pathologic activities in autoimmune diseases. The cynomolgus...
6.
Carr D, Ayehunie S, Davies A, Duckworth C, French S, Hall N, et al.
Pharmacol Ther
. 2017 Jan;
172:181-194.
PMID: 28132905
Adverse drug reactions affecting the gastrointestinal (GI) tract are a serious burden on patients, healthcare providers and the pharmaceutical industry. GI toxicity encompasses a range of pathologies in different parts...
7.
Tseng H, Gage J, Haisler W, Neeley S, Shen T, Hebel C, et al.
Sci Rep
. 2016 Aug;
6:30640.
PMID: 27477945
Vasoactive liabilities are typically assayed using wire myography, which is limited by its high cost and low throughput. To meet the demand for higher throughput in vitro alternatives, this study...
8.
Potter W, ORiordan K, Barnett D, Osting S, Wagoner M, Burger C, et al.
PLoS One
. 2010 Feb;
5(2):e8996.
PMID: 20126541
Long Term Potentiation (LTP) is a leading candidate mechanism for learning and memory and is also thought to play a role in the progression of seizures to intractable epilepsy. Maintenance...